MX2023002389A - Compuestos moduladores de gpr52. - Google Patents

Compuestos moduladores de gpr52.

Info

Publication number
MX2023002389A
MX2023002389A MX2023002389A MX2023002389A MX2023002389A MX 2023002389 A MX2023002389 A MX 2023002389A MX 2023002389 A MX2023002389 A MX 2023002389A MX 2023002389 A MX2023002389 A MX 2023002389A MX 2023002389 A MX2023002389 A MX 2023002389A
Authority
MX
Mexico
Prior art keywords
gpr52
sup
modulator compounds
compounds
ameliorating
Prior art date
Application number
MX2023002389A
Other languages
English (en)
Inventor
Michael Alistair O'brien
Sarah Joanne Bucknell
Stephen Paul Watson
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of MX2023002389A publication Critical patent/MX2023002389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Las descripciones en la presente se relacionan a compuestos novedosos de la Fórmula (1): (VER FORMULA); O una sal de estos, en donde se definen en la presente Q, V, L, W, R1 y R2 , y su uso en el tratamiento, prevención, mejora, control o reducir el riesgo de los trastornos asociados con los receptores GPR52.
MX2023002389A 2020-08-28 2021-08-31 Compuestos moduladores de gpr52. MX2023002389A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2013558.8A GB202013558D0 (en) 2020-08-28 2020-08-28 GRP52 Modularor compounds
PCT/GB2021/052247 WO2022043714A1 (en) 2020-08-28 2021-08-31 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
MX2023002389A true MX2023002389A (es) 2023-05-03

Family

ID=72749711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002389A MX2023002389A (es) 2020-08-28 2021-08-31 Compuestos moduladores de gpr52.

Country Status (12)

Country Link
US (1) US20230348416A1 (es)
EP (1) EP4204408A1 (es)
JP (1) JP2023539336A (es)
KR (1) KR20230058132A (es)
CN (1) CN116507622A (es)
AU (1) AU2021330379A1 (es)
BR (1) BR112023003696A2 (es)
CA (1) CA3193487A1 (es)
GB (1) GB202013558D0 (es)
IL (1) IL301007A (es)
MX (1) MX2023002389A (es)
WO (1) WO2022043714A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784316T3 (es) 2015-04-29 2020-09-24 Arena Pharm Inc 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo
ES2895904T3 (es) * 2015-11-02 2022-02-23 Genase Therapeutics B V Tetrahidroindazoles y usos médicos de los mismos
CN114650992A (zh) * 2019-11-08 2022-06-21 赫普泰雅治疗有限公司 Gpr52调节剂化合物

Also Published As

Publication number Publication date
KR20230058132A (ko) 2023-05-02
EP4204408A1 (en) 2023-07-05
GB202013558D0 (en) 2020-10-14
US20230348416A1 (en) 2023-11-02
AU2021330379A1 (en) 2023-03-30
CN116507622A (zh) 2023-07-28
IL301007A (en) 2023-05-01
WO2022043714A1 (en) 2022-03-03
BR112023003696A2 (pt) 2023-04-04
JP2023539336A (ja) 2023-09-13
CA3193487A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2022010040A (es) Compuestos moduladores de gcn2.
MX2022011333A (es) Compuestos moduladores de gpr52.
MX2022005111A (es) Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52).
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
MY135841A (en) Novel benzodioxoles
DE602004011394D1 (en) Thiazolderivate
MX2022012474A (es) Compuestos y usos de estos.
MX2022009309A (es) Compuestos y usos de los mismos.
MX2020002824A (es) Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
EP4249054A3 (en) Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
MX2023010303A (es) Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
MX2022009369A (es) Compuestos y usos de estos.
MX2022009308A (es) Compuestos y usos de estos.
MX2021006029A (es) Pamoato de ketamina y su uso.
MX2022009367A (es) Compuestos y usos de estos.
MX2021011286A (es) Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia.
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
MX2022011613A (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina ii.
CR20130055A (es) Compuestos aromáticos apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
PH12019501566A1 (en) Amide compounds and use thereof
MX2023002389A (es) Compuestos moduladores de gpr52.
DE60016181D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge